Clarke Anthony 4/A
4/A · ACHIEVE LIFE SCIENCES, INC. · Filed Aug 11, 2017
Insider Transaction Report
Form 4/AAmended
Clarke Anthony
DirectorPresident & CSO
Transactions
- Award
Common Stock
2017-08-01+359,305→ 359,305 total(indirect: By Spouse) - Award
Common Stock
2017-08-01+176,418→ 176,418 total(indirect: By Ricanto Limited) - Award
Common Stock
2017-08-01+550,455→ 550,455 total - Award
Common Stock
2017-08-01+538,958→ 538,958 total(indirect: By Son)
Footnotes (5)
- [F1]This amended Form 4 is filed to correct the number of common shares received in exchange for 1,532 common shares of Achieve Life Science, Inc. ("Achieve") pursuant to the merger between OncoGenex Pharmaceuticals, Inc. ("OncoGenex") and Achieve (the "Merger"). On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect an 11-for-1 reverse stock split effected on August 1, 2017 (the "Reverse Stock Split").
- [F2]This amended Form 4 is filed to correct the number of common shares received in exchange for 1,000 common shares of Achieve pursuant to the Merger. On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect the Reverse Stock Split.
- [F3]This amended Form 4 is filed to correct the number of common shares received in exchange for 1,500 common shares of Achieve pursuant to the Merger. On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect the Reverse Stock Split.
- [F4]This amended Form 4 is filed to include the number of common shares received in exchange for 491 common shares of Achieve pursuant to the Merger. On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect the Reverse Stock Split.
- [F5]The reporting holder is a principal owner of Ricanto Limited.